Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
41 tokens/sec
GPT-4o
60 tokens/sec
Gemini 2.5 Pro Pro
44 tokens/sec
o3 Pro
8 tokens/sec
GPT-4.1 Pro
50 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

ChatGPT in Drug Discovery: A Case Study on Anti-Cocaine Addiction Drug Development with Chatbots (2308.06920v2)

Published 14 Aug 2023 in cs.AI, cs.HC, and q-bio.BM

Abstract: The birth of ChatGPT, a cutting-edge LLM-based chatbot developed by OpenAI, ushered in a new era in AI. However, due to potential pitfalls, its role in rigorous scientific research is not clear yet. This paper vividly showcases its innovative application within the field of drug discovery. Focused specifically on developing anti-cocaine addiction drugs, the study employs GPT-4 as a virtual guide, offering strategic and methodological insights to researchers working on generative models for drug candidates. The primary objective is to generate optimal drug-like molecules with desired properties. By leveraging the capabilities of ChatGPT, the study introduces a novel approach to the drug discovery process. This symbiotic partnership between AI and researchers transforms how drug development is approached. Chatbots become facilitators, steering researchers towards innovative methodologies and productive paths for creating effective drug candidates. This research sheds light on the collaborative synergy between human expertise and AI assistance, wherein ChatGPT's cognitive abilities enhance the design and development of potential pharmaceutical solutions. This paper not only explores the integration of advanced AI in drug discovery but also reimagines the landscape by advocating for AI-powered chatbots as trailblazers in revolutionizing therapeutic innovation.

User Edit Pencil Streamline Icon: https://streamlinehq.com
Authors (3)
  1. Rui Wang (996 papers)
  2. Hongsong Feng (15 papers)
  3. Guo-Wei Wei (128 papers)
Citations (22)